Geovax (GOVX) Patents And Unique Viral Meds, Going Up 🆙

daz888888888
2023-03-16

$GeoVax Labs Inc(GOVX)$ 

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, announced today that it will report 2022 financial results on Thursday, March 23, 2023 after the market closes.

Following the release, management will host a live conference call and webcast to provide a general business update and discuss financial results. Subsequent to management’s prepared remarks, there will be a Q&A period for analysts and others.

Thursday, March 23, 2023, 4:30 PM ET

Domestic: 877-269-7756

International: 201-689-7817

Conference ID: 13736454

Webcast: GeoVax 2022 Earnings Webcast

A webcast replay of the call will be available via the same link as the live webcast approximately one hour after the end of the call through June 23, 2023.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in two Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a COVID-19 vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient. In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website: www.geovax.com

💰 Stocks to watch today?(29 Mar)
1. What news/movements are worth noting in the market today? Any stocks to watch? 2. What trading opportunities are there? Do you have any plans? 🎁 Make a post here, everyone stands a chance to win Tiger coins!
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

  • JC888
    2023-03-16
    JC888
    Too many biotech n pharma companies listed. Investing in them is like speculating.
    Decided not to anymore.
    Still reeling in Reds with those that I have.
    Luckily it's token investment. Still money that could have been invested elsewhere...
  • YorkTurner
    2023-03-18
    YorkTurner
    Marketcap under cash position. Will hit $3-5 sooner or later imho. ZIKA vaccin only 1 of the few possible winners.
  • Bons
    2023-03-16
    Bons
    I'm not sure whether the health sector will have a boost in the past covid era
  • fishinglo
    2023-03-18
    fishinglo
    Just imagine what this would mean for GOVX if they could do the same for one of the many vaccins in development. Market cap is just ~25mln.
  • shining87
    2023-03-18
    shining87
    Any positive news can ignite this 'cash value only' vaccin company. Can easily go 5-10X with positive product news.
  • YeddaJohnson
    2023-03-18
    YeddaJohnson
    Govx vaccine so more safer attacks more strain one shot fact track please
Leave a comment
34
1